About Market Research Forecast

MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.

Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.

Anti-Inflammatory Biologics Market

Anti-Inflammatory Biologics Market 2025-2033 Overview: Trends, Competitor Dynamics, and Opportunities

Anti-Inflammatory Biologics Market by Drug Class (Anti-Tumor Necrosis Factor (TNF), by Application (Rheumatoid Arthritis, Psoriasis, Others), by Route of Administration (Oral, Injection (Subcutaneous, Intravenous), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), by By Geography (North America) Forecast 2026-2034

Aug 14 2025

Base Year: 2025

180 Pages

Anti-Inflammatory Biologics Market 2025-2033 Overview: Trends, Competitor Dynamics, and Opportunities

Key Insights

The Anti-Inflammatory Biologics Market size was valued at USD 93.13 USD billion in 2023 and is projected to reach USD 139.11 USD billion by 2032, exhibiting a CAGR of 5.9 % during the forecast period. A Therapeutic categorized as the anti-inflammatory biologic is defined to mediate inflammation by focusing on the specific molecules that are involved in the inflammatory process. These biologics, of living beings, are called monoclonal antibodies and cytokine inhibitors. Unlike that of conventional anti-inflammatory drugs, which work throughout the body, biologics offer precise targeting with only moderate systemic side effects. They are typically employed to treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease where the immune system attacks the body, instead. In modulating the immune response, anti-inflammatory biologics, therefore, help reduce the manifestation of symptoms, improve life quality, and prevent damage to the tissues of patients with chronic inflammatory conditions, which gives us the right to believe that personalized medicine and quality patient care will be good.

Anti-Inflammatory Biologics Trends

Growing prevalence of chronic inflammatory diseases.
Advancement in biotechnology and the development of novel biologics.
Rising demand for personalized and targeted therapies.
Increasing healthcare spending in emerging markets.

Anti-Inflammatory Biologics Market Market Size and Forecast (2024-2030) — Anti-Inflammatory Biologics Market Company Market Share

Driving Forces: What's Propelling the Anti-Inflammatory Biologics Market

Rising prevalence of chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Government initiatives to support research and development in the field of biologics.
Increasing awareness of new and innovative biologic therapies among healthcare professionals and patients.
Growing acceptance of biologics as first-line treatment options.

Challenges and Restraints in Anti-Inflammatory Biologics Market

Sustained High Cost of Biologics and Treatment Regimens: The exorbitant cost of biologics and the associated treatment regimens continue to pose significant financial challenges for patients and healthcare systems. The high manufacturing costs, research and development expenses, and administration fees contribute to the overall burden.
Safety Concerns and Potential Side Effects: Biologics, while effective, carry the potential for side effects and safety issues. These include the risk of infections (due to immune system suppression), infusion reactions, gastrointestinal issues, and rare but severe autoimmune conditions.
Limited Accessibility in Underserved Areas: Access to anti-inflammatory biologics in developing countries and underserved regions remains limited due to financial constraints, infrastructure challenges, and lack of trained healthcare professionals. This disparity affects patient outcomes and widens disparities in healthcare access.
Competition from Biosimilars and Generic Substitutes: The emergence of biosimilars and generic drugs has increased competition in the anti-inflammatory biologics market. While these alternatives offer similar efficacy and tolerability, they typically come at a lower cost, challenging the market share of branded biologics.
Complex Regulatory Landscape: The regulatory approval process for biologics is stringent and involves extensive clinical trials and thorough assessments. This can delay the availability of new biologics and increase development costs for manufacturers.

Emerging Trends in Anti-Inflammatory Biologics

Development of new biologics with improved efficacy and safety profiles.
Growing use of personalized medicine to tailor treatment to individual patients.
Advancements in drug delivery systems to enhance bioavailability and reduce side effects.
Increased focus on combination therapies to improve treatment outcomes.

Growth Catalysts in Anti-Inflammatory Biologics Industry

Advancements in Biotechnology and Drug Delivery: Significant breakthroughs in genetic engineering, advanced cell culture techniques, antibody engineering (including bispecific antibodies and antibody-drug conjugates), and innovative drug delivery systems (e.g., targeted nanoparticles) are continuously expanding the therapeutic landscape of anti-inflammatory biologics. This leads to novel agents with enhanced specificity, efficacy, reduced immunogenicity, and improved tolerability profiles, ultimately driving market growth.
Robust Government Support and Funding Initiatives: Governments globally are actively investing in the development and commercialization of anti-inflammatory biologics. This support, encompassing substantial grants, tax incentives, expedited regulatory pathways, and collaborative research programs, fuels innovation and accelerates the introduction of new and improved therapies to the market.
Rising Prevalence of Chronic Inflammatory Diseases and Growing Awareness: The escalating global burden of chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and others, is a primary driver of market expansion. Simultaneously, increasing awareness among healthcare professionals and patients about the superior efficacy and targeted nature of biologics compared to traditional therapies is fostering greater adoption rates.
Precision Medicine and Targeted Therapies: Biologics represent a cornerstone of precision medicine, offering highly targeted therapies that precisely modulate specific inflammatory pathways or neutralize key pro-inflammatory molecules. This targeted approach minimizes off-target effects, leading to improved patient outcomes and a stronger market position for these therapies. The development of personalized medicine strategies based on biomarkers is further enhancing the effectiveness and value proposition of these biologics.
Expansion of Biosimilar and Biobetter Development: The emergence of biosimilar and biobetter medications is increasing competition and driving down prices, making these treatments more accessible to a wider patient population. This increased accessibility further fuels market expansion while simultaneously promoting cost-effectiveness within healthcare systems.

Market Segmentation: Anti-Inflammatory Biologics Analysis

Drug Class

Anti-Tumor Necrosis Factor (TNF)
Anti-Interleukin (IL)
Anti-Integrin
Others

Application

Rheumatoid Arthritis
Psoriasis
Inflammatory Bowel Disease
Others

Route of Administration

Oral
Injection (Subcutaneous and Intravenous)

Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Leading Players in the Anti-Inflammatory Biologics Market

Significant Developments in the Anti-Inflammatory Biologics Sector

February 2023: Pfizer Inc. announced the approval of its supplemental New Drug Application (sNDA) for CIBINQO by the U.S. FDA for patients suffering from moderate-to-severe atopic dermatitis.

March 2022: AbbVie announced the U.S. FDA’s approval of RINVOQ (upadacitinib) for the treatment of adults suffering from ulcerative colitis.

October 2022: GSK plc provided an update on the ContRAst phase III program for otilimab, an investigational monoclonal antibody used in the potential treatment of moderate to severe rheumatoid arthritis.

September 2022: Bristol Myers Squibb announced two-year results from the POETYK PSO Long-Term Extension (LTE) trial with continuous Sotyktu treatment in adult patients diagnosed with plaque psoriasis.

December 2021: Pfizer Inc. announced the approval of Cibinqo (abrocitinib), an oral, once-daily, Janus Kinase 1 (JAK1) inhibitor, for the treatment of Atopic Dermatitis (AD) by the European Commission (EC).

Comprehensive Coverage Anti-Inflammatory Biologics Market Report

Comprehensive analysis of the global anti-inflammatory biologics market.
In-depth insights into market dynamics, trends, and drivers.
Detailed segmentation of the market by drug class, application, route of administration, and distribution channel.
Profiles of leading players and their market shares.
Analysis of industry developments and their impact on the market.
Forecast of the market size and growth rate for the coming years.

Regional Insight

Market analysis reveals significant regional variations in the adoption and growth of anti-inflammatory biologics. North America and Europe currently hold substantial market shares, driven by factors such as high healthcare expenditure, advanced healthcare infrastructure, and early adoption of innovative therapies. However, the Asia-Pacific region exhibits strong growth potential due to the increasing prevalence of chronic inflammatory diseases, rising disposable incomes, and expanding healthcare access. Latin America and the Middle East and Africa also present opportunities for market expansion, albeit at varying paces, contingent upon factors such as economic development and healthcare system improvements.

Anti-Inflammatory Biologics Market Market Share by Region - Global Geographic Distribution — Anti-Inflammatory Biologics Market Regional Market Share

DROCT

Drivers: Rising prevalence of chronic inflammatory diseases, technological advancements, and government support for research and innovation.
Restraint: High cost of biologics, potential side effects, and limited access in developing countries.
Opportunities: Development of new biologics, personalized medicine, and combination therapies.
Challenges: Competition from biosimilars and generic drugs.
Threats: Potential safety concerns and reimbursement issues.

Pricing Analysis

The cost of anti-inflammatory biologics varies widely depending on the drug, dosage, and frequency of administration.
The average cost of a course of treatment for rheumatoid arthritis ranges from USD 5,000 to USD 20,000 per year.

Import And Export Analysis

The United States is the largest market for anti-inflammatory biologics, followed by Europe and Japan.
The major exporters of anti-inflammatory biologics are the United States, Switzerland, and Ireland.
The major importers of anti-inflammatory biologics are China, Japan, and Brazil.

Patent/Trademark Analysis

The patent landscape for anti-inflammatory biologics is complex and evolving.
Several major patents for anti-inflammatory biologics are set to expire in the coming years, which could lead to increased competition and lower prices.
Companies are also actively pursuing trademarks to protect their brand names and differentiate their products.

Geographic Coverage of Anti-Inflammatory Biologics Market

Higher Coverage

Lower Coverage

No Coverage

Anti-Inflammatory Biologics Market REPORT HIGHLIGHTS

Aspects	Details
Study Period	2020-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2020-2025
Growth Rate	CAGR of 5.9 % from 2020-2034
Segmentation	By Drug Class Anti-Tumor Necrosis Factor (TNF By Application Rheumatoid Arthritis Psoriasis Others By Route of Administration Oral Injection (Subcutaneous Intravenous By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy By Geography By Geography North America

1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
- 2.1. Introduction
3. Market Dynamics
- 3.1. Introduction
- - 3.2. Market Drivers
  - - 3.2.1. Rising Prevalence of Inflammatory Diseases to Favor Market Growth
- - 3.3. Market Restrains
  - - 3.3.1. Lack of Inclination for Biologics as First Line of Treatment to Restrict Market Growth
- - 3.4. Market Trends
  - - 3.4.1. Transition from Anti-Tumor Necrosis Factor (TNF) to Non-Anti-Tumor Necrosis Factor (TNF) to Treat Inflammatory Diseases
4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
5. Global Anti-Inflammatory Biologics Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
  - 5.1.1. Anti-Tumor Necrosis Factor (TNF
- 5.2. Market Analysis, Insights and Forecast - by Application
  - 5.2.1. Rheumatoid Arthritis
  - 5.2.2. Psoriasis
  - 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast - by Route of Administration
  - 5.3.1. Oral
  - 5.3.2. Injection (Subcutaneous
  - 5.3.3. Intravenous
- 5.4. Market Analysis, Insights and Forecast - by Distribution Channel
  - 5.4.1. Hospital Pharmacy
  - 5.4.2. Retail Pharmacy
  - 5.4.3. Online Pharmacy
- 5.5. Market Analysis, Insights and Forecast - by Region
  - 5.5.1. By Geography
6. Competitive Analysis
- 6.1. Global Market Share Analysis 2025
- - 6.2. Company Profiles
  - - 6.2.1 AbbVie Inc. (U.S.)
      6.2.1.1. Overview
      6.2.1.2. Products
      6.2.1.3. SWOT Analysis
      6.2.1.4. Recent Developments
      6.2.1.5. Financials (Based on Availability)
    - 6.2.2 Merck & Co. Inc. (U.S.)
      6.2.2.1. Overview
      6.2.2.2. Products
      6.2.2.3. SWOT Analysis
      6.2.2.4. Recent Developments
      6.2.2.5. Financials (Based on Availability)
    - 6.2.3 Bristol-Myers Squibb Company (U.S.)
      6.2.3.1. Overview
      6.2.3.2. Products
      6.2.3.3. SWOT Analysis
      6.2.3.4. Recent Developments
      6.2.3.5. Financials (Based on Availability)
    - 6.2.4 Johnson & Johnson Services Inc. (U.S.)
      6.2.4.1. Overview
      6.2.4.2. Products
      6.2.4.3. SWOT Analysis
      6.2.4.4. Recent Developments
      6.2.4.5. Financials (Based on Availability)
    - 6.2.5 Pfizer Inc. (U.S.)
      6.2.5.1. Overview
      6.2.5.2. Products
      6.2.5.3. SWOT Analysis
      6.2.5.4. Recent Developments
      6.2.5.5. Financials (Based on Availability)
    - 6.2.6 Novartis AG (Switzerland)
      6.2.6.1. Overview
      6.2.6.2. Products
      6.2.6.3. SWOT Analysis
      6.2.6.4. Recent Developments
      6.2.6.5. Financials (Based on Availability)
    - 6.2.7 UCB S.A. (Belgium)
      6.2.7.1. Overview
      6.2.7.2. Products
      6.2.7.3. SWOT Analysis
      6.2.7.4. Recent Developments
      6.2.7.5. Financials (Based on Availability)
    - 6.2.8 Eli Lilly and Company (U.S.)
      6.2.8.1. Overview
      6.2.8.2. Products
      6.2.8.3. SWOT Analysis
      6.2.8.4. Recent Developments
      6.2.8.5. Financials (Based on Availability)
    - 6.2.9 Amgen Inc. (U.S.)
      6.2.9.1. Overview
      6.2.9.2. Products
      6.2.9.3. SWOT Analysis
      6.2.9.4. Recent Developments
      6.2.9.5. Financials (Based on Availability)
    - 6.2.10 Biogen (U.S.)
      6.2.10.1. Overview
      6.2.10.2. Products
      6.2.10.3. SWOT Analysis
      6.2.10.4. Recent Developments
      6.2.10.5. Financials (Based on Availability)

List of Figures

Figure 1: Global Anti-Inflammatory Biologics Market Revenue Breakdown (USD Billion, %) by Region 2025 & 2033
Figure 2: By Geography Anti-Inflammatory Biologics Market Revenue (USD Billion), by Drug Class 2025 & 2033
Figure 3: By Geography Anti-Inflammatory Biologics Market Revenue Share (%), by Drug Class 2025 & 2033
Figure 4: By Geography Anti-Inflammatory Biologics Market Revenue (USD Billion), by Application 2025 & 2033
Figure 5: By Geography Anti-Inflammatory Biologics Market Revenue Share (%), by Application 2025 & 2033
Figure 6: By Geography Anti-Inflammatory Biologics Market Revenue (USD Billion), by Route of Administration 2025 & 2033
Figure 7: By Geography Anti-Inflammatory Biologics Market Revenue Share (%), by Route of Administration 2025 & 2033
Figure 8: By Geography Anti-Inflammatory Biologics Market Revenue (USD Billion), by Distribution Channel 2025 & 2033
Figure 9: By Geography Anti-Inflammatory Biologics Market Revenue Share (%), by Distribution Channel 2025 & 2033
Figure 10: By Geography Anti-Inflammatory Biologics Market Revenue (USD Billion), by Country 2025 & 2033
Figure 11: By Geography Anti-Inflammatory Biologics Market Revenue Share (%), by Country 2025 & 2033

List of Tables

Table 1: Global Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Drug Class 2020 & 2033
Table 2: Global Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Application 2020 & 2033
Table 3: Global Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Route of Administration 2020 & 2033
Table 4: Global Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Distribution Channel 2020 & 2033
Table 5: Global Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Region 2020 & 2033
Table 6: Global Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Drug Class 2020 & 2033
Table 7: Global Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Application 2020 & 2033
Table 8: Global Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Route of Administration 2020 & 2033
Table 9: Global Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Distribution Channel 2020 & 2033
Table 10: Global Anti-Inflammatory Biologics Market Revenue USD Billion Forecast, by Country 2020 & 2033
Table 11: North America Anti-Inflammatory Biologics Market Revenue (USD Billion) Forecast, by Application 2020 & 2033

Methodology

Step 1 - Identification of Relevant Samples Size from Population Database

Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.

Note*: In applicable scenarios

Step 3 - Data Sources

Primary Research

Web Analytics
Survey Reports
Research Institute
Latest Research Reports
Opinion Leaders

Secondary Research

Annual Reports
White Paper
Latest Press Release
Industry Association
Paid Database
Investor Presentations

Step 4 - Data Triangulation

Involves using different sources of information in order to increase the validity of a study

These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.

Frequently Asked Questions

1. What is the projected Compound Annual Growth Rate (CAGR) of the Anti-Inflammatory Biologics Market?

The projected CAGR is approximately 5.9 %.

2. Which companies are prominent players in the Anti-Inflammatory Biologics Market?

Key companies in the market include AbbVie Inc. (U.S.), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), UCB S.A. (Belgium), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Biogen (U.S.).

3. What are the main segments of the Anti-Inflammatory Biologics Market?

The market segments include Drug Class, Application, Route of Administration, Distribution Channel.

4. Can you provide details about the market size?

The market size is estimated to be USD 93.13 USD Billion as of 2022.

5. What are some drivers contributing to market growth?

Rising Prevalence of Inflammatory Diseases to Favor Market Growth.

6. What are the notable trends driving market growth?

Transition from Anti-Tumor Necrosis Factor (TNF) to Non-Anti-Tumor Necrosis Factor (TNF) to Treat Inflammatory Diseases.

7. Are there any restraints impacting market growth?

Lack of Inclination for Biologics as First Line of Treatment to Restrict Market Growth.

8. Can you provide examples of recent developments in the market?

February 2023 - Pfizer Inc. announced the approval of its supplemental New Drug Application (sNDA) for CIBINQO by the U.S. FDA for patients suffering from moderate-to-severe atopic dermatitis.

9. What pricing options are available for accessing the report?

Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4850, USD 5850, and USD 6850 respectively.

10. Is the market size provided in terms of value or volume?

The market size is provided in terms of value, measured in USD Billion.

11. Are there any specific market keywords associated with the report?

Yes, the market keyword associated with the report is "Anti-Inflammatory Biologics Market," which aids in identifying and referencing the specific market segment covered.

12. How do I determine which pricing option suits my needs best?

The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

13. Are there any additional resources or data provided in the Anti-Inflammatory Biologics Market report?

While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.

14. How can I stay updated on further developments or reports in the Anti-Inflammatory Biologics Market?

To stay informed about further developments, trends, and reports in the Anti-Inflammatory Biologics Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

Get Free Sample

Pre Order Enquiry Request discount

Pricing

Related Reports

U.S. Anti-Inflammatory Biologics Market Report Probes the USD Billion Size, Share, Growth Report and Future Analysis by 2033

Anti-Inflammatory Drugs Market 2025-2033 Analysis: Trends, Competitor Dynamics, and Growth Opportunities

Inflammatory Bowel Disease Treatment Market Soars to 26.55 USD billion , witnessing a CAGR of 5.8 during the forecast period 2025-2033

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Is Set To Reach 15.58 USD billion By 2033, Growing At A CAGR Of 21.2

Rheumatoid Arthritis Therapeutics Market XXX CAGR Growth Outlook 2025-2033

Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
Customized Evaluation of Competitive Landscape to Meet Your Needs
Tailored Customization to Address Other Specific Requirements

Ask for customization

The response was good, and I got what I was looking for as far as the report. Thank you for that.

Erik Perison

US TPS Business Development Manager at Thermon

As requested- presale engagement was good, your perseverance, support and prompt responses were noted. Your follow up with vm’s were much appreciated. Happy with the final report and post sales by your team.

Shankar Godavarti

Global Product, Quality & Strategy Executive- Principal Innovator at Donaldson

I have received the report already. Thanks you for your help.it has been a pleasure working with you. Thank you againg for a good quality report